News

COPD Patients Unaware of Their Higher Risk for Lung Cancer, Study Shows

Patients with chronic obstructive pulmonary disease (COPD) are unaware of their increased lung cancer risk compared with the general population — attributing their chest symptoms to factors other than potential cancer signs, according to a study. The researchers recommended campaigns to raise awareness about this risk since early lung cancer detection…

Orion’s Easyhaler, Propeller’s Digital Platform Will Help Monitor COPD, Asthma Treatment

Orion and Propeller Health have established a collaboration to offer a custom sensor and mobile app to digitally monitor medication use with Easyhaler — a metered-dose dry powder inhaler for the treatment of chronic obstructive pulmonary disease (COPD) and asthma. Developed by Orion and available across Europe, Easyhaler is a line of…

Statins Linked to Better Outcomes and Improved Lung Function in COPD Patients, Meta-analysis Finds

Statins, commonly used to lower blood cholesterol levels, can help chronic obstructive pulmonary disease (COPD) patients by preventing or treating COPD-related comorbidities, and by improving patients’ lung function and exercise capacity, according to a meta-analysis study of existing research data. Results from the meta-analysis, titled “Effectiveness of long-term using…

First Generic Version of COPD Inhaler Advair Diskus Approved by FDA

The first generic version of the inhalation treatment Advair Diskus (fluticasone/salmeterol powder) was recently approved by the U.S. Food and Drug Administration for chronic obstructive pulmonary disease (COPD) and asthma patients. According to a press release from developer Mylan, the therapy, called Wixela Inhub (fluticasone propionate and salmeterol inhalation powder),…

Physicians Are First in U.S. to Perform Robotic-assisted Lung Surgery

Physicians at Illinois’ Northwestern Memorial Hospital are the first in the United States to successfully perform a robotic-assisted lung volume reduction surgery (LVRS) to extract diseased tissue from the lungs of patients with severe emphysema, a progressive form of chronic obstructive pulmonary disease (COPD). The first procedure was done in late…

Ensifentrine Shows Benefit as Add-on Maintenance Therapy in Phase 2 Trial, Verona Pharma Says

Data from a three-day Phase 2 clinical trial offered positive results for nebulized ensifentrine (RPL544) as an add-on treatment for chronic obstructive pulmonary disease (COPD), its developer Verona Pharma announced. Ensifentrine is an inhibitor of phosphodiesterase (PDE) proteins PDE3 and PDE4, which are involved in smooth muscle contraction and immune cell-derived inflammation, respectively.